MedPath

Pulmonary RehabIlitation with Nasal-high-flow-support in COPD and Effectiveness: The PRINCE study

Completed
Conditions
chronic bronchitis
Emphysema
10006436
Registration Number
NL-OMON46686
Lead Sponsor
CIRO+ Horn
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
80
Inclusion Criteria

- - Patients with COPD with hypoxia which at least demand 1 liter oxygen/min during baseline.
- Clinical stable on the basis of clinical picture by the chest physician.
- Documented desaturation during exercise, which demands at least 2 liters oxygen/min to correct.
- Permission for voluntary participation. Patient will be asked during the start of their rehabilitation program and have to sign an informed consent. Patients have the right to withdraw from the study without any negative consequences on their rehabilitation.
- Attending the regular rehabilitation program in CIRO+.

Exclusion Criteria

- Lack of motivation for voluntary participation in the present study.
- Not capable to understand the instruction of the NHF oxygen delivery system
- Outpatient pulmonary rehabilitation program in a hospital which is part of the CIRO network.
- Not capable to perform cycle tests, walk tests and/or endurance training on a cycle ergometer and treadmill.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The main study parameter is the increase in cycle endurance time after<br /><br>completion of the PR program and 6 months after completion of the PR program. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary study parameters are changes in 6-min walking distance (6MWD),<br /><br>increase in training intensity, oxygen saturation, heart rate, Borg scores for<br /><br>dyspnoea and fatigue, lung function, health status and the number of<br /><br>exacerbations and hospitalizations. Long term outcome measures for the<br /><br>follow-up period are lung function, cycle endurance time, daily symptoms and<br /><br>the number of exacerbations and hospitalizations.</p><br>
© Copyright 2025. All Rights Reserved by MedPath